Controversial

Large Boutiques: PWP, CVP (esp Biotech/Pharma), EVR

BBs: GS, JPM, MS

MM: Cowen, SVB, HW, WB

 

SVB has taken a big hit - cantor is extremely good for HC. #4 in follow on transactions since 2017 (when sage kelly finally got settled in), only near JP, Jefferies and I think GS. they also have plenty of m&a and a relatively new Debt MD

 

Jefferies piper for sure as well with all mentioned previously. Would also add jmp after being acquired by citizens and potentially RJ

 
Most Helpful

this one comes back every so often. 

this for example:

https://www.wallstreetoasis.com/forum/investment-banking/best-healthcar…

it's hard because not everyone does everything and excels at it.

are you looking at fees? fees per banker? number of deals? specific verticals? specific types of deals (ECM or M&A? sponsor or corporates)...

a few things that stand out:

- JPMorgan probably consistently across all market segments. lots of bodies on the ground. covers all verticals

- some MM firms have very specific angles. Piper dominates in med tech for example. also fees share of Piper, SVB, Cowen for biotech IPO is impressive. for M&A less so (Piper was doing well on spec pharma M&A but their top banker left for Barclays (which is incidentally strong on spec pharma).

sell-side biotech? centerview #1 by far; Lazard fighting for share too. JPmorgan growing presence.

Large cap pharma advisory? most EBs (albeit don't print with every large pharma - exceptions are probably Evercore and Centerview); then JP / MS / GS / BAML (no specific order). Citi somewhat behind; others are more aligned with specific corporates.

CDMO? beyond thre BBs, RBC had a strong market share, but top CDMO banker left for Truist. 

HL is focused on buy & build, also good presence in healthcare marketing companies. some good presence in medtech too (notably Europe, although team is recent)

Jefferies is strong across verticals, quite MM focused, M&A is PE focused as well

 

I think SVBs M&A fees last year were pretty sizeable. About 50%+ of their revenue was from m&a

 

Services kills it volume-wise, pharma still holds a lot of big relationships but low activity from them (besides equity stuff), and unsure what the deal is with medtech after the junior turnover / culture problems. Definitely solid as a whole platform

 

HL, Jeffries, Moelis. for all things services / retail / multi site. You’ll see some BBs win mandates in this vertical obviously but not at the same velocity. I’d say HL wins the most but will average smaller deal size wise.

I don’t know a ton about the other verticals but I know Baird has a pretty solid pharma services platform out in Charlotte.

SVB and Tripletree also have great groups but I’d say are a slight cut below the rest.

 

Veniam qui omnis nam eius ipsum. Quis iste facere architecto non cumque sequi.

Maxime consequatur quo omnis ea quo laboriosam ut cum. Labore quia rerum fugit earum est.

Deleniti qui vero dolor rerum suscipit et. Laboriosam quos quod rem eos in repellat. Nisi eius recusandae sint ut aut iure. Perferendis dolorem ut voluptatem optio sed consequatur.

Harum qui impedit maiores itaque velit reiciendis. Earum architecto ea architecto ipsa vero ea id. Enim sit consectetur quo delectus eos mollitia.

 

Provident atque nesciunt et. Quidem tempore et sed sequi aut soluta. Dolore et consectetur officia officia aut. Sint odio blanditiis aut tenetur harum debitis est. Vel quae adipisci ea omnis. Quia dicta vel et quam. Ad vero consequatur reiciendis.

Aut non quam consequatur. Magnam consectetur nostrum dicta suscipit. Placeat praesentium doloremque praesentium et et quas et et. Recusandae accusamus maiores dolor sit nemo eos et. Maxime laborum quisquam reprehenderit vitae.

Career Advancement Opportunities

April 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

April 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

April 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

April 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (86) $261
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (145) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Betsy Massar's picture
Betsy Massar
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
GameTheory's picture
GameTheory
98.9
6
dosk17's picture
dosk17
98.9
7
kanon's picture
kanon
98.9
8
CompBanker's picture
CompBanker
98.9
9
numi's picture
numi
98.8
10
DrApeman's picture
DrApeman
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”